Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of allocating more funding for research into (a) myalgic encephalomyelitis and (b) long covid.

The Department funds research in health and social care through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of long COVID and myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and are actively exploring next steps for research in these areas. This includes a roundtable I hosted on long COVID on 17 October 2024, which included discussion on how long COVID research is relevant to other post-viral syndromes and how to stimulate the research community to undertake future research.

Over the last five years, the NIHR has invested almost £2.3 million in research programme funding for ME/CFS. In addition, the NIHR and the MRC are also providing £3.2 million of co-funding towards the DecodeME study, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.

In the same period, the Government, through the NIHR and the MRC, has invested over £57 million in long COVID research, with almost £40 million of this through two specific research calls on long COVID. The NIHR specifically has invested £42.7 million towards research funding for long COVID. The projects funded aim to improve our understanding of the diagnosis and underlying mechanisms of the disease and the effectiveness of both pharmacological and non-pharmacological therapies and interventions, as well as to evaluate clinical care.

The NIHR welcomes funding applications for research into any aspect of human health including ME/CFS and long COVID. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity.

Publishing the consultation response and delivery plan for ME/CFS is a key priority for me.